Integrated ReportFiscal Year Ended Mar. 31, 2020
Our Company
Our Strategy
- For a Sustainable Society and Company Development
- Four Key Components of Our Corporate Strategy
- Component A：Focus Our Corporate Portfolio
- Component B：Further Strengthen Leadership in Endoscopy
- Component C：Focus and Scale Our TSD Business
- Component D：Lead in Next-Generation Minimally Invasive Surgery
- COO and CTO Dialogue
- Scientific Solutions Division
- Imaging Division
- Message from the CAO
- Transform Olympus Leaders’ Perspectives
- Evolving Our Corporate Culture
Our Setup
- Directors
- Governance Roundtable Discussion
- Corporate Governance
- Risk Management
- Compliance
- Information Security
- Links to CSR Data Book
- Information Disclosure
Data
- Financial / Non-Financial Highlights
- 10-Year Financial / Non-Financial Data
- Risk Information
- Consolidated Financial Statements and Notes
- Independent Auditor’s Report
- Corporate Information / Stock Information
- FY Ended Mar. 31, 2025
- FY Ended Mar. 31, 2024
- FY Ended Mar. 31, 2023
- FY Ended Mar. 31, 2022
- FY Ended Mar. 31, 2021
- FY Ended Mar. 31, 2020
- FY Ended Mar. 31, 2019
- FY Ended Mar. 31, 2018
- FY Ended Mar. 31, 2017
- FY Ended Mar. 31, 2016
- FY Ended Mar. 31, 2015
- FY Ended Mar. 31, 2014
- FY Ended Mar. 31, 2013
- FY Ended Mar. 31, 2012
Olympus Group's detailed ESG data are included in the CSR data book
CSR Data Book